je.st
news
Tag: study
Study: How climate change threatens mountaintops (and clean water)
2017-01-25 23:00:00| LifeSciencesWorld
[NEWS] Mountains are far more than rocks. About half of the world's drinking water filters through their high-elevation forests, plants, and soils, among other natural benefits. Now, a new first-of-its kind study, in the journal Nature, shows how these mountain ecosystems around the globe may be threatened by climate change. Rising temperatures over the next decades appear likely to “decouple” key nutrient cycles in mountain soils and plants, an international team of…
Tags: change
study
water
clean
Study finds parrotfish are critical to coral reef health
2017-01-22 23:00:00| LifeSciencesWorld
[NEWS] IMAGE: This image shows the extraction of reef sediment core off the coast of Bocas del Toro, Panama. Credit: Scripps Oceanography/Richard Norris An analysis of fossilized parrotfish teeth and sea urchin spines by researchers at Scripps Institution of Oc…
Tags: health
study
critical
finds
Success Case Study: YO-HO Brewing Company
2016-12-20 09:54:00| Beverage industry market research - from just-drinks.com
Japan's beer market, which is heavily dominated by lager and lager-style beer, has been seeing continual decline for decades. Although the volume share of ale and stout is very small in Japan, registe
Tags: company
case
study
success
Success Case Study: Mio Sparkling Sake
2016-12-20 09:54:00| Beverage industry market research - from just-drinks.com
Saké is a traditional Japanese still rice wine made from fermented polished rice. It typically has an ABV of 15-16%. In Japan, the sales volume of saké has gradually declined for over a decade and los
Interim Results from Phase 1b/2 Study Evaluating the Combination of Mercks KEYTRUDA (pembrolizumab) and Eisais HALAVEN (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer Presented at 2016 SABCS
2016-12-12 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & WOODCLIFF LAKE, N.J. KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new interim data investigating Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with Eisais microtubule dynamics inhibitor, HALAVEN (eribulin), in patients with metastatic triple-negative breast cancer (TNBC). Language: English Contact: Media:MerckPamela Eisele, 267-305-3558orKim Hamilton, (908) 740-1863orEisai Inc.Laurie Landau, 201-746-2510orInvestors:MerckTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898orEisai Inc.Ivor Macleod, 201-746-2660 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: results
study
presented
combination
Sites : [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239] [240] next »